While we can count many successes from our 2013-18 Antimicrobial Resistance (AMR) Strategy, resistance has continued to increase. In the United Kingdom we have seen a 35% increase in resistant blood stream infections in humans from 2013-17.<\/p>
The number of bloodstream infections (BSIs) is increasing each year. Although the proportion of antibiotic resistant BSIs remain stable year to year, the burden on resistance increases. This is mostly due to increasing prevalence of E.coli bloodstream infections.<\/p>
Estimates of the multi-resistant cases can be made, however not all the bacteria are tested against the same antibiotics, so a definitive number of cases cannot be given. The Public Health England Fingertips tool also has an indicator showing the rolling quarterly average proportion of E. coli blood specimens non-susceptible to at least three of the key antimicrobials (gentamicin, ciprofloxacin, piperacillin/tazobactam, 3rd-generation cephalosporins or carbapenems). For England this is 5.5% with little fluctuation over time.<\/p>
This is exactly why the UK\u2019s five-year national action plan for AMR, published alongside the UK 20-year vision for AMR on 24 January 2019, includes a strengthened focus on infection prevention and control, renewing our commitment to halve levels of healthcare associated Gram-negative blood stream infections (mostly E.coli) by 2023-24. The plan also sets a world-first target to reduce the actual numbers of resistant infections, with the aim to reduce them by 10% by 2025.<\/p>
We are working with the devolved health administrations to develop consistent methodologies for reporting the incidence and mortality of key antibiotic resistant infections and antimicrobial use to allow us to report progress on the ambitions of the AMR national action plan.<\/p>
As reductions in inappropriate prescribing also reduces the risk of promoting the growth of antibiotic-resistant bacteria, interventions to reduce antibiotic prescribing or transmission of the bacteria are complementary.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"} } , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"} , "dateOfAnswer" : {"_value" : "2019-05-14", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-14T16:29:42.253Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-04-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Antibiotics: Drug Resistance"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what assessment they have made of the effectiveness of their 2013\u201318 antimicrobial resistance strategy at addressing the problem of multi-resistant E. coli-like bacteria; what assessment they have made of recent trends in the number of multi-resistant E. coli-like bacteria in the UK; and what factors inform their view of the balance between efforts to reduce transmission and efforts to reduce the use of antibiotics.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3596", "label" : {"_value" : "Biography information for Baroness Gardner of Parkes"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Gardner of Parkes"} ], "uin" : "HL15384"} , {"_about" : "http://data.parliament.uk/resources/1092659", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1092659/answer", "answerText" : {"_value" : "
The project to develop and test the feasibility of new models that pay companies for antimicrobials based primarily on a heath technology assessment of their value to the National Health Service as opposed to the volumes used, and to share the learning with international stakeholders, is expected to be established by July this year.<\/p>
<\/p>
The NHS Long Term Plan, published in January this year, makes the commitment to implement the human health aspects of \u2018Tackling Antimicrobial Resistance (2019-2024): the UK\u2019s five-year national action plan\u2019. The project will be led by a central project team resourced by the National Institute for Health and Care Excellence and NHS England and the National Institute for Health Research Policy Research Programme is considering research to support the process.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"} } , "answeringMemberConstituency" : {"_value" : "Thurrock"} , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"} , "dateOfAnswer" : {"_value" : "2019-03-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-03-29T14:35:37.427Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-03-21", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Antibiotics: Drug Resistance"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the Tackling antimicrobial resistance 2019\u20132024: The UK\u2019s five-year national action plan, published on 24 January 2019, what plans he has to fund the (a) design and (b) testing of a new economic model for antibiotics.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4382", "label" : {"_value" : "Biography information for Daniel Zeichner"} } , "tablingMemberConstituency" : {"_value" : "Cambridge"} , "tablingMemberPrinted" : [{"_value" : "Daniel Zeichner"} ], "uin" : "235308"} , {"_about" : "http://data.parliament.uk/resources/884937", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/884937/answer", "answerText" : {"_value" : "
The Department has provided the following funding for research on antimicrobial resistance, the majority of which will have been directed at research on tackling antibiotic-resistant bacteria.<\/p>
<\/p>
Financial Year<\/p><\/td> | Funding provided<\/p><\/td><\/tr> |
2015/16<\/p><\/td> | £11,617,633<\/p><\/td><\/tr> |
2016/17<\/p><\/td> | £17,727,228<\/p><\/td><\/tr> |
2017/18<\/p><\/td> | £30,565,100<\/p><\/td><\/tr><\/tbody><\/table> <\/strong><\/p> It is possible that a small number of programmes or projects on antibiotic-resistant bacteria also include research on other drug-resistant microbes or pathogens; it is not possible to separate out this funding from the above totals.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"}
}
, "answeringMemberConstituency" : {"_value" : "Gosport"}
, "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"}
, "dateOfAnswer" : {"_value" : "2018-04-24", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-04-24T11:17:43.597Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-04-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Antibiotics: Drug Resistance"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what funding his Department has provided for research on tackling antibiotic-resistant bacteria in each of the last three years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4418", "label" : {"_value" : "Biography information for Justin Madders"}
}
, "tablingMemberConstituency" : {"_value" : "Ellesmere Port and Neston"}
, "tablingMemberPrinted" : [{"_value" : "Justin Madders"}
], "uin" : "135925"}
, {"_about" : "http://data.parliament.uk/resources/828153", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/828153/answer", "answerText" : {"_value" : " The English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) run by Public Health England has made a national assessment of prescribing patterns by general practices and clinical commissioning groups, together with an assessment of trends in antibiotic resistance among the most common types of bacteria causing serious infections. ESPAUR publishes annual reports and the most recent report, published in October 2017, is available at the following link:<\/p> <\/p> |